At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 823 enrolled
Drug / intervention
Finerenone (BAY94-8862) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
In Brief
A Phase 2 clinical trial evaluating Finerenone (BAY94-8862) and Placebo for Diabetic Nephropathies. Completed, enrolled 823 participants across 147 sites in 23 countries.
Detailed Summary
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Nephropathies
CountriesAustralia, Austria, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJun 2013
Primary CompletionJul 2014
Study CompletionAug 2014
TodayJul 2026
First PostedJun 11, 2013
Enrollment StartJun 12, 2013
Primary CompletionJul 9, 2014
Study CompletionAug 7, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.1 years ago
Interventions
Finerenone (BAY94-8862)drug
Placebodrug